NO20044282L - Selektiv malstyring til tumorvaskulatur ved anvendelse av antistoffmolekyler - Google Patents

Selektiv malstyring til tumorvaskulatur ved anvendelse av antistoffmolekyler

Info

Publication number
NO20044282L
NO20044282L NO20044282A NO20044282A NO20044282L NO 20044282 L NO20044282 L NO 20044282L NO 20044282 A NO20044282 A NO 20044282A NO 20044282 A NO20044282 A NO 20044282A NO 20044282 L NO20044282 L NO 20044282L
Authority
NO
Norway
Prior art keywords
antibody molecules
domain
employed
tumor vasculature
template control
Prior art date
Application number
NO20044282A
Other languages
English (en)
Inventor
Christoph-Stephan Hilger
Barbara Carnemolla
Enrica Balza
Patrizia Castellani
Luciano Zardi
Laura Borsi
Matthias Friebe
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of NO20044282L publication Critical patent/NO20044282L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Optics & Photonics (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
NO20044282A 2002-03-11 2004-10-08 Selektiv malstyring til tumorvaskulatur ved anvendelse av antistoffmolekyler NO20044282L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36304502P 2002-03-11 2002-03-11
PCT/IB2003/001458 WO2003076469A2 (en) 2002-03-11 2003-03-11 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature

Publications (1)

Publication Number Publication Date
NO20044282L true NO20044282L (no) 2004-10-08

Family

ID=27805258

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044282A NO20044282L (no) 2002-03-11 2004-10-08 Selektiv malstyring til tumorvaskulatur ved anvendelse av antistoffmolekyler

Country Status (22)

Country Link
US (1) US8491906B2 (no)
EP (2) EP1483297B1 (no)
JP (2) JP2005534283A (no)
KR (1) KR100983385B1 (no)
CN (1) CN100535013C (no)
AT (1) ATE452912T1 (no)
AU (1) AU2003219370B2 (no)
BR (1) BRPI0308376B8 (no)
CA (1) CA2478414C (no)
CY (1) CY1109820T1 (no)
DE (1) DE60330652D1 (no)
DK (1) DK1483297T3 (no)
ES (1) ES2337566T3 (no)
IL (1) IL212702A0 (no)
MX (1) MXPA04008810A (no)
NO (1) NO20044282L (no)
PL (1) PL374386A1 (no)
PT (1) PT1483297E (no)
RU (1) RU2347787C2 (no)
SI (1) SI1483297T1 (no)
WO (1) WO2003076469A2 (no)
ZA (1) ZA200408107B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
EP1816475A1 (en) * 2004-07-22 2007-08-08 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
WO2007128557A1 (en) * 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
ATE548052T1 (de) 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
KR100998569B1 (ko) * 2008-03-31 2010-12-07 한국원자력연구원 암 또는 전이암 진단 및 치료용 방사면역접합체，및 이를이용한 암 또는 전이암 억제제 개발
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
EP3029065B1 (en) * 2013-06-06 2020-05-27 Hefei Lifeon Pharmaceutical Co. Ltd. Human antibody against ed-b domain of fibronectin and uses thereof
JP7039577B2 (ja) 2016-10-17 2022-03-22 ファイザー・インク 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CN111148759B (zh) * 2017-09-30 2023-09-19 合肥立方制药股份有限公司 结合至纤维连接蛋白b结构域的蛋白
UY38074A (es) 2018-02-09 2019-10-01 Philogen Spa Composiciones de edb que se dirigen a il-12
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
JP7352040B2 (ja) 2020-05-22 2023-09-27 フィロジェン エッセ．ピー．アー． 脳腫瘍の治療のためのＴＮＦα免疫コンジュゲート療法
AU2023206004A1 (en) 2022-01-04 2024-08-22 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
WO2024028258A1 (en) 2022-08-01 2024-02-08 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
WO2024052333A1 (en) 2022-09-06 2024-03-14 Philochem Ag Multivalent fibroblast activation protein ligands for targeted delivery applications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2547061B1 (fr) * 1983-06-01 1985-07-05 Commissariat Energie Atomique Procede pour determiner l'activite volumique et estimer la masse de plutonium contenu dans des dechets et dispositif pour la mise en oeuvre de ce procede
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0627932B1 (en) * 1992-11-04 2002-05-08 City Of Hope Antibody construct
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE60121733T2 (de) 2000-02-24 2007-08-09 Philogen S.P.A. Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen
EP1259548A1 (en) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
EP1130099A1 (en) * 2000-02-25 2001-09-05 Crucell Holland B.V. Activated vitronectin as a marker of angiogenesis detected with phage antibodies
CA2468081A1 (en) 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B

Also Published As

Publication number Publication date
SI1483297T1 (sl) 2010-04-30
RU2004130428A (ru) 2005-08-27
US8491906B2 (en) 2013-07-23
DE60330652D1 (de) 2010-02-04
KR20040097163A (ko) 2004-11-17
DK1483297T3 (da) 2010-05-03
ATE452912T1 (de) 2010-01-15
PT1483297E (pt) 2010-03-29
CY1109820T1 (el) 2014-09-10
US20060057146A1 (en) 2006-03-16
AU2003219370A1 (en) 2003-09-22
JP2005534283A (ja) 2005-11-17
JP2009268470A (ja) 2009-11-19
RU2347787C2 (ru) 2009-02-27
EP1483297B1 (en) 2009-12-23
PL374386A1 (en) 2005-10-17
ES2337566T3 (es) 2010-04-27
BRPI0308376B8 (pt) 2021-05-25
EP2174958A1 (en) 2010-04-14
BRPI0308376A2 (pt) 2016-06-28
CA2478414C (en) 2012-11-13
CN100535013C (zh) 2009-09-02
MXPA04008810A (es) 2005-09-08
BRPI0308376B1 (pt) 2020-03-10
CN1639195A (zh) 2005-07-13
CA2478414A1 (en) 2003-09-18
KR100983385B1 (ko) 2010-09-20
WO2003076469A2 (en) 2003-09-18
EP1483297A2 (en) 2004-12-08
WO2003076469A3 (en) 2003-11-27
WO2003076469A9 (en) 2005-09-29
IL212702A0 (en) 2011-07-31
ZA200408107B (en) 2005-12-28
AU2003219370B2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
IL212702A0 (en) Selective targeting of tumor vasculature using antibody molecules
Natsch et al. The specific biochemistry of human axilla odour formation viewed in an evolutionary context
WO2004048525A3 (en) Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
HUP0102992A2 (hu) Szcintigráfiai célokat szolgáló specifikus kötőmolekulák, a molekulákat tartalmazó konjugátumok és az angiogenezis kezelésére szolgáló terápiás eljárások
ATE377027T1 (de) Tetravalente antikörperkonstrukte
ATE431417T1 (de) Mutationen in der mit der resistenz gegenüber sti-571 assoziierten bcr-abl-tyrosinkinase
ATE386117T1 (de) Prostattumor polynukleotid- und antigenzusammensetzungen
DK1409654T3 (da) Immunologisk styring af beta-amyloid-niveauer in vivo
ATE239506T1 (de) Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
ATE276763T1 (de) Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
DE60320009D1 (de) Transplant-Akzeptanz induzierende Zellen monocytären ursprungs, sowie deren Herstellung und Verwendung
ATE466072T1 (de) Bandscheibe
DK0433088T3 (da) Monoklonale antistoffer, der reagerer med et humant atheromaassocieret antigen
WO2002003857A3 (en) Method of tissue modulation for noninvasive measurement of an analyte
WO2004019893A3 (en) Modulators of angiogenesis
UA89759C2 (ru) Специфический связующий элемент, радиоактивно меченный 131и, который связывает человеческий ed-в фибронектина
Kobayashi et al. Toward in vivo imaging of heart disease using a radiolabeled single-chain Fv fragment targeting tenascin-C
Vrathasha et al. Mechanisms of cellular internalization of quantum dot® conjugated bone formation mimetic peptide CK2. 3
Li et al. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine
ATE361096T1 (de) Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
DE60123434D1 (de) Mit schizophrenie zusammenhängendes gen und protein
ITFI990094A1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraverso la determinazione dell'isoforma ctn-c della tn-c,frammenti di
ATE348161T1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
Bogdanov et al. Synthesis and testing of a binary catalytic system for imaging of signal amplification in vivo
DE60336214D1 (de) Methoden zur analyse von antikörperdisulfidisomere

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application